Clindamycin is commonly used in the treatment of Staphylococcus aureus. In vitro routine tests for clindamycin susceptibility may fail to detect inducible clindamycin resistance due to erm genes resulting in treatment failure, thus necessitating the need to detect such resistance by a simple D test on routine basis. 140 Staphylococcus aureus isolates were subjected to routine antibiotic susceptibility testing including oxacillin (1µg) by Kirby Bauer disc diffusion method. 
Staphylococcus aureus infections are important causes of nosocomial and community acquired infections. Treatment of these infections is a growing problem due to increasing Methicillin resistance among Staphylococci.
1 The MacrolideLincosamide-Streptogramin B (MLS B ) family of antibiotics serve as an alternative treatment option, with clindamycin being the preferred agent due to its excellent pharmacokinetic properties. 2 However, widespread use of MLS B antibiotics has led to an increase in number of Staphylococcal strains acquiring resistance to MLS B antibiotics.
3
Macrolide resistance may be due to enzymes encoded by a variety of erm genes-MLS B phenotype or active efflux pump encoded by the mrsA gene-MS phenotype. MLS B resistance can be either constitutive (c MLS B ) or inducible (i MLS B ). 4 In constitutive resistance, in vitro susceptibility tests show resistance to both erythromycin and clindamycin. In inducible resistance, in vitro susceptibility tests show resistance to erythromycin, but susceptibility to clindamycin, unless induced by erythromycin. iMLS B resistance can not be determined by using standard susceptibility test methods, but can be determined by erythromycin-clindamycin disc approximation test (D test).
The aim of the present study was to determine the prevalence of inducible clindamycin resistance in both Methicillin resistant and susceptible strains of Staphylococcus aureus in clinical isolates and also susceptibility pattern of the isolates in our hospital.
Subjects & Methods
The present study was conducted for a period of 2 years from January 2007 to December 2008 and included a total of 140 isolates of Staphylococcus aureus from specimens of Pus/ Wound swabs, Respiratory tract infections and Body fluids. The S. arueus were identified by using standard microbiological procedures.
5 Antibiotic susceptibility tests were performed by Kirby Bauer disc diffusion method on Mueller Hinton agar plates using Erythromycin (15µg),Clindamycin (2µg), (Fig.3) 
3.
Constitutive resistance(c MLS B phenotype):-Resistant to both erythromycin to clindamycin. (Fig. 2) 4.
Sensitive phenotype: -Sensitive to both erythromycin to clindamycin. 
DISCUSSION
Due to the increasing Nosocomial MRSA infections which are multidrug resistant treatment option is very limited. Vancomycin due to its high cost and possibility of emergence of resistance; it is not widely used by clinicians. 7 Clindamycin due to its tolerability, cost, oral form and good tissue penetration remains alternative treatment option for skin and soft tissue infections. 8 But there are reports of iMLS B resistance in the clinical isolates [2] [3] [4] [7] [8] [9] [10] [11] [12] . So it is essential to detect the inducible resistance to avoid therapeutic failure in patients.
In our study iMLS B resistance was 6.42%. cMLS B resistance was 5.71%. Similar findings of higher inducible resistance were reported by Angel et al (64% vs. 00%) and Shantala G B et al (24.89% vs. 18.26%).
9,10 Deotale et al., (14.5% vs. 3.6%).
11
However in MRSA cMLS B resistance (12.5%) was higher than that of iMLS B resistance (10.93%).Many studies have reported similar results-Gadepalli et al reported 38% cMLSB resistance and 30 % iMLSB resistance. 3 Gupta et al reported 46% cMLSB resistance and 20 % iMLSB resistance. 12 Debdas et al reported 23% cMLSB resistance and 18 % iMLSB resistance.
Interestingly cMLSB resistance was not seen in MSSA. Similar result was reported by Angel et al only.
The antibiotic susceptibility patterns of i MLS B isolates in this study showed that treatment options are very limited due to multidrug resistant strains. So clindamycin is the preferred drug for the treatment and for that D test must be performed to avoid therapeutic failure.
In conclusion, to avoid the therapeutic failure, the D test must be performed by all laboratories routinely while reporting the sensitivity against clindamycin in staphylococcal infections.
